Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 18 Neoplasm Metastasis 2 Prostatic Neoplasms, Castration-Resistant 1 Prostate Adenocarcinoma 1 Pain 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Metastatic Castration-resistant Prostate Cancer 1 Fatigue 1 Castration-resistant Prostate Cancer 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Biochemical Recurrent Prostate Cancer 1

Interventions

enzalutamide 20 Abiraterone Acetate 11 Prednisone 7 Docetaxel 7 radium Ra 223 dichloride 6 darolutamide 5 abiraterone 5 apalutamide 3 olaparib 2 niraparib 2 cabazitaxel 2 atezolizumab 2 Pluvicto 2 Nivolumab 2 zimberelimab 1 xentuzumab 1 tasquinimod 1 sacituzumab govitecan 1 sabizabulin 1 quemliclustat 1 pembrolizumab 1 ipatasertib 1 ibrutinib 1 gedatolisib 1 gallium 68 PSMA-11 1 fludrocortisone acetate 1 TVB-2640 1 Standard of Care 1 Rosuvastatin Calcium 1 Radium-223 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Prostatic Neoplasms, Castration-Resistant × Radium-223 × Clear all

NCT03563014 2020-05-20

BELFIGO

Bayer

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡